Advanced in Primary Tubular Proximal Acidosis

Massimo Di Maio

Turin, IT 
Advanced in Primary Tubular Proximal Acidosis
Turin, IT 
OverviewLocationsClinical Research

Overview

Massimo Di Maio practices in Turin, Italy. Mr. Di Maio is rated as an Advanced expert by MediFind in the treatment of Primary Tubular Proximal Acidosis. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Orchiectomy, and Nephrectomy.

His clinical research consists of co-authoring 493 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Primary Tubular Proximal Acidosis.

Gender
Male

Locations

Turin, Italy
Other Locations
Orbassano, Italy
Italy
Piemonte, Italy
Milan, Italy
Naples, Italy
Cura, Italy
Reggio Nell'emilia, Italy
Salerno, Italy
Rossano, 87068, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Qualitative and Quantitative Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Their Hospitalization in Neonatology
Qualitative and Quantitative Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Their Hospitalization in Neonatology
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Other
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2023
Intervention Type: Drug
Study Drugs: Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs
Study Phase: Phase 2
View 1 Less Clinical Trial

493 Total Publications

Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica.
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica.
Journal: Tumori
Published: October 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Di Maio's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile